{ 
    "name": "AbbVie",
    "symbol": "ABBV",
    "type": "stock",
    "price": 100.00,
    "drugs": [
        {
            "name": "Humira",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Venclexta",
            "mechanism": "BCL2 inhibitor",
            "indication": "CLL",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            },
            "economics": "Roche partnership"
        },
        {
            "name": "Rinvoq",
            "mechanism": "JAK inhibitor",
            "indication": "RA",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Skyrizi",
            "mechanism": "IL-23 inhibitor",
            "indication": "Psoriasis",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Mavyret",
            "mechanism": "NS5A inhibitor",
            "indication": "Hepatitis C",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Botox",
            "mechanism": "Botulinum toxin",
            "indication": "Aesthetic",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Imbruvica",
            "mechanism": "BTK inhibitor",
            "indication": "CLL",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Lupron",
            "mechanism": "GnRH-a agonist",
            "indication": "Prostate cancer",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Synthroid",
            "mechanism": "Thyroid hormone",
            "indication": "Hypothyroidism",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Creon",
            "mechanism": "Pancreatic enzyme",
            "indication": "Chronic pancreatitis",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Restasis",
            "mechanism": "",
            "indication": "Dry eye",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        },
        {
            "name": "Duodopa",
            "mechanism": "L-DOPA",
            "indication": "Parkinson's disease",
            "revenue": {
                "2023": 1000000000,
                "2022": 900000000,
                "2021": 800000000
            }
        }
    ]
}
